Transanal Versus Laparoscopic Total Mesorectal Excision: a Prospective Observational Cohort
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rectal Cancer
- Sponsor
- Sun Yat-sen University
- Enrollment
- 2502
- Primary Endpoint
- disease-free survival ratev
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study was to compare the long-term oncology outcomes and specimen quality of taTME and laTME in the treatment of middle and low rectal cancer by a large sample cohort. At the same time, the local recurrence following a primary rectal cancer resection was analyzed to respond to the concerns about the event of the national suspension for TaTME due to the high local recurrence rate in Norway.
Detailed Description
Laparoscopic surgery is considered to have better visualization for more accurate separation and further injury reduction than open surgery. However, the oncology outcomes are still controversial. Especially in the challenging patients who have narrow and deep pelvic, the disadvantage that it is difficult to obtain high-quality resected specimens during laparoscopic TME (laTME) surgery is considered to be magnified. It is considered transanal total mesorectal excision (taTME) is an alternative method to solve this "old problem". However, as a new technology that has been around for only 10 years, the applicability of taTME worldwide needs to be further proved in long-term oncology. This prospective cohort study aimed to compare taTME surgery to laTME surgery for mid and low-rectal cancer on long-term oncology outcomes from a single, experienced Chinese center that was an early adopter of taTME.
Investigators
Yanhong Deng
Professor
Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •Age between 18 and 80 years old
- •Confirmed rectal adenocarcinoma cancer pathologically
- •Tumor location ≦ 12 cm from the anal margin
- •Willing and able to provide written informed consent for participation in this study
Exclusion Criteria
- •Distant metastasis before surgery
- •More than one colorectal tumor at diagnosis
- •Familial adenomatous polyposis
- •Recurrent rectal cancer
- •Undergo transanal minimally invasive surgery
- •Undergo palliative treatment
- •Undergo emergency surgery
Outcomes
Primary Outcomes
disease-free survival ratev
Time Frame: 5 years after the surgery
Overall survival rate
Time Frame: 5 years after the surgery
Secondary Outcomes
- Cancer special survival rate(5 years after the surgery)
- CRM status(30 days after the surgery)
- DRM status(30 days after the surgery)
- Quality of the mesorectum specimen(30 days after the surgery)
- Local recurrence rate(3 years after the surgery)